Jeena Mary Varghese, M.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Interests
For physician to physician referrals, please call our main office line at (713) 792-2841.
For new adult patient self referrals, please call our new patient referral coordinators at (713) 563-4400 or visit us at https://my.mdanderson.org/
International patients may complete this form International Center or contact the International Center at 001-713-745-0450.
For general department information, please select the link below or call us at (713) 792-2841. Thank you.
Department of Endocrine Neoplasia and Hormonal Disorders
Education & Training
Degree-Granting Education
| 2003 | Adichunchanagiri Institute of Medical Sciences, Bellur, IN, Medical School, MBBS |
Postgraduate Training
| 2010-2011 | Clinical Research Fellowship, Advanced Endocrinology, Diabetes and Metabolism, The University of Texas Health Science Center and The University of Texas MD Anderson Cancer Center, Houston |
| 2008-2010 | Clinical Fellowship, Endocrinology, Diabetes and Metabolism, The University of Texas Health Science Center at Houston Medical School, Houston, Texas |
| 2006-2008 | Clinical Residency, Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas |
| 2005-2006 | Clinical Internship, Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas |
| 1996-2003 | Undergraduate, Adichunchanagiri Institute of Medical Sciences, Bellur |
Licenses & Certifications
| 2024 | Alabama Board of Medical Examiners |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2023 | Georgia Composite Medical Board |
| 2021 | Florida Board of Medicine |
| 2017 | The American Board of Medical Quality |
| 2011 | American Board of Internal Medicine, Endocrinology, Diabetes and Metabolism |
| 2010 | Texas Medical License |
| 2008 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022
Assistant Professor, The University of Texas Health Science at Houston, Houston, 2012 - 2016
Physician, Hospital Privileges, Memorial Hermann Hospital, Houston, TX, 2012 - 2016
Physician, Hospital Privileges, Lyndon B. Johnson Hospital - Harris County Hospital District, Houston, TX, 2012 - 2016
Administrative Appointments/Responsibilities
Co-Director, Bone Health Clinic, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Rotation Site Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Hospital, Houston, TX, 2020 - Present
Other Professional Positions
Co Chair Memorial Hermann Hospital Glycemic Task Force, Memorial Hermann Hospital, Houston, TX, 2015 - 2016
Division Quality Officer, The University of Texas Health Science Center Medical School, Houston, 2014 - 2016
Medical Director of Endocrinology, Lyndon B. Johnson General Hospital, Houston, TX, 2014 - 2016
Intramural Institutional Committee Activities
Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Extramural Institutional Committee Activities
Member, SRC, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Hypercalcemia Workgroup, The University of Texas MD Anderson Cancer Center, 2023 - Present
Chair, APP Endocrine Neoplasia Hormonal Disorders Educational Series, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Member, Clinical Competency Committee, Baylor College of Medicine, 2020 - Present
Team Lead, Glycemic Task Force, Education Subcommittee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Clinical Effectiveness Subcommittee, The University of Texas MD Anderson Cancer Center, 2019 - 2025
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Editorial Activities
Section and Page Editor, HemOnc.org, 2018 - 2020
Honors & Awards
| 2021 | Top Provider, MD Anderson |
| 2020 | Rising Star, Super Doctors |
| 2019 | Rising Star, Super Doctors |
| 2019 | Top Provider, MD Anderson |
| 2016 | Winner QI Project- Electronic Consultation (E-Consults): Improving Access to Endocrine Specialty Care in Harris Health System, The University of Texas Health Science Center - Houston Medical School |
| 2016 | Edward Randall, III, Internal Medicine Quality Fair |
| 2016 | Dean's Teaching Excellence Award, The University of Texas Medical School at Houston |
| 2015 | Dean's Teaching Excellence Award, The University of Texas Medical School at Houston |
| 2015 | Rising Star, Super Doctors |
| 2014 | Dean's Teaching Excellence Award, The University of Texas Medical School at Houston |
| 2014 | Rising Star, Super Doctors |
| 2013 | Rising Star, Super Doctors |
| 2013 | Dean's Teaching Excellence Award, The University of Texas Medical School at Houston |
| 2012 | Dean's Teaching Excellence Award, The University of Texas Medical School at Houston |
| 2010 | Travel Grant, 14th International Congress and American Thyroid Association |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Unmasking Pheochromocytoma and Paraganglioma. Invited. Houston, Texas, US.
- 2025. Thyroid Emergencies. Invited. Fellows Lecture. Houston, Texas, US.
- 2024. Adrenal Insufficiency. Invited. APP Educational Talk. Houston, Texas, US.
- 2024. Cushing's Syndrome. Invited. APP Educational Talk. Houston, Texas, US.
- 2023. Bone Health Management for Cancer Survivors. Invited. Cancer Survivorship. Houston, Texas, US.
- 2022. Pheochromocytoma/Paraganglioma. Conference. Pheochromocytoma/Paraganglioma. Houston, TX, US.
- 2022. Paragangliomas. Conference. Paragangliomas. Houston, TX, US.
- 2022. Endocrine IO related Toxicities and Management. Conference. Endocrine IO related Toxicities and Management. Houston, TX, US.
- 2022. Caring for Your Bones During Cancer. Conference. Caring for Your Bones During Cancer. Houston, TX, US.
- 2021. Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. Invited. ENDO2021 Highlights, US.
- 2020. Male Hypogonadism. Invited. Endocrine Faculty Education Series. Houston, Texas, US.
- 2020. Adrenocortical Cancer. Conference. Adrenocortical Cancer. Houston, TX, US.
- 2019. Post Thyroidectomy Calcium Management. Conference. Post Thyroidectomy Calcium Management. Houston, TX, US.
- 2018. Post Thyroidectomy Calcium Management. Conference. Post Thyroidectomy Calcium Management. Houston, TX, US.
- 2018. Medical Physics Students. Invited. Houston, Texas, US.
- 2013. Pheochromocytoma and Paraganglioma. Invited. Pheochromocytoma and Paraganglioma. Houston, TX, US.
- 2012. Pheochromocytoma and Paraganglioma-An Update. Invited. Pheochromocytoma and Paraganglioma-An Update. Dallas, TX, US.
- 2010. Ultrasonographic Patterns of Thyroid Nodules. Invited. Ultrasonographic Patterns of Thyroid Nodules. San Antonio, TX, US.
- Adrenal Multidisciplinary Meeting. Panelist. Houston, Texas, US.
- Metabolic Bone Multidisciplinary Group. Panelist. Houston, Texas, US.
National Presentations
- 2025. Bone Health in Cancer Patients. Invited. APP Oncology Summit. Denver, US.
- 2025. Bone Health in Cancer Patients. Invited. APP Oncology Summit. Nashville, Tennessee, US.
- 2025. Bone Health in Cancer Patients. Invited. APP Oncology Summit. Georgetown, Texas, US.
- 2023. Indications for genetic Testing in Adrenal Tumors. Invited. TXEA/TESS Annual Meeting. Houston, Texas, US.
- 2017. Pheochromocytoma and Paragangliomas, Medical Education Program on Neuroendocrine Tumors. Conference. Pheochromocytoma and Paragangliomas, Medical Education Program on Neuroendocrine Tumors. Houston, TX, US.
- 2009. Large Adenoma with Multiple Foci of Encapsulated Micro Papillary Thyroid Cancer. Conference. Large Adenoma with Multiple Foci of Encapsulated Micro Papillary Thyroid Cancer. Palm Beach, FL, US.
International Presentations
- 2018. Updates in the Management of Malignant Pheochromocytoma. Conference. 13th Update on the Management of Genitourinary Malignancies. Houston, US.
- 2010. Role of Cytotoxic Chemotherapy in Advanced Differentiated Thyroid Cancer–Review of the MD Anderson Experience. Conference. Role of Cytotoxic Chemotherapy in Advanced Differentiated Thyroid Cancer–Review of the MD Anderson Experience. Paris, FR.
Formal Peers
- 2016. Outpatient Management of Diabetes in Adults. Invited. Houston, TX, US.
- 2016. Perioperative Glucose Management. Invited. Houston, TX, US.
- 2014. Adjuvant Therapy in Differentiated Thyroid Cancer. Invited. Houston, TX, US.
- 2013. Thyroid Nodules. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 4-[18F]Fluoro-1-Naphthol ([18F]4FN) for PET Imaging |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21 |
| Date: | 2023 - 2026 |
| Title: | A Phase II Study to evaluate the efficacy and safety of pembrolizumab in combination with mitotane in patients with advanced adrenocortical carcinoma |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | 2022-0705 |
| Date: | 2021 - 2027 |
| Title: | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations |
| Funding Source: | Merck Sharp & Dohme LLC |
| Role: | Co-I |
| ID: | 2021-0270 |
| Date: | 2020 - 2023 |
| Title: | A Phase 1b, Open-Label Study of Relacorilant in Combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production |
| Funding Source: | Concept Therapeutics |
| Role: | Co-Investigator, 0% effort |
| ID: | 2020-0562 |
| Date: | 2020 - 2024 |
| Title: | Development of the Thyroid Cancer Quality of Life Index |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Collaborator, 0% effort |
| Date: | 2018 - 2020 |
| Title: | Smoking Related Oxidative Stress and Risk of Adrenocortical Carcinoma |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | Co-PI |
| ID: | 2018-08-28T11 |
| Date: | 2018 - 2020 |
| Title: | Quality of life in patients undergoing lobectomy vs total thyroidectomy in low risk papillary thyroid cancer |
| Funding Source: | MD Anderson Cancer Center / Survivorship |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Quality of life in patients undergoing lobectomy vs total thyroidectomy in low risk papillary thyroid cancer |
| Funding Source: | MD Anderson Cancer Center / IRG |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | A Phase II Study the Evaluate the Effects of Cabozantinib in Patients with Unresectable/Metastatic Adrenocortical Carcinoma |
| Funding Source: | Exelixis & The University of Texas MD Anderson Cancer Center |
| Role: | Collaborator, 0% effort |
| ID: | 2016-0741 |
| Date: | 2014 - 2021 |
| Title: | A Phase II Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-Investigator, 0% effort |
| ID: | 2014-0081 |
Selected Publications
Peer-Reviewed Articles
- Szabo Yamashita, T, Tame-Elorduy, A, Skefos, CM, Varghese, J, Habra, MA, Fisher, SB, Graham, PH, Grubbs, EG, Waguespack, SG, Jimenez, C, Perrier, ND. SDHB-Associated Pheochromocytomas. Annals of surgical oncology 31(13):9007-9013, 2024. e-Pub 2024. PMID: 39382746.
- Varghese, J, Skefos, CM, Jimenez, C. Metastatic pheochromocytoma and paraganglioma. Molecular and cellular endocrinology 592, 2024. e-Pub 2024. PMID: 39182716.
- Al-Ward R, Brondani VB, Sawani S, Potter CL, Xu G, Waguespack SG, Varghese J, Habra MA, Lu Y, Jimenez C. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med 49(7):610-620, 2024. e-Pub 2024. PMID: 38630996.
- Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist 29(7):575-580, 2024. e-Pub 2024. PMID: 38776552.
- Jimenez C, Habra MA, Campbell MT, Tamsen G, Cruz-Goldberg D, Long J, Bassett R, Dantzer R, Balderrama-Brondani V, Varghese J, Lu Y. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. The Lancet Oncology 25(5):658-667, 2024. e-Pub 2024. PMID: 38608693.
- Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 25(5):649-657, 2024. e-Pub 2024. PMID: 38608694.
- Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract 30(1):25-30, 2024. e-Pub 2024. PMID: 37858722.
- Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, Habra MA, Graham P, Waguespack SG. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 108(5):1132-1142, 2023. e-Pub 2023. PMID: 36433823.
- Jeun R, Iyer PC, Best C, Lavis V, Varghese J, Yedururi S, Brady V, Glitza Oliva IC, Dadu R, Milton DR, Brock K, Thosani S. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy 15(6):417-428, 2023. e-Pub 2023. PMID: 37013834.
- Varghese J, Daher M, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
- Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers, 2022. e-Pub 2022.
- Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
- Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological Risk Factors for Adrenocortical Carcinoma: A Hospital-based Case-Control Study. Int J Cancer 146(7):1836-1840, 2020. e-Pub 2020. PMID: 31241762.
- Golant BT, Velez-Perez A, Krishnamurthy S, Guo M, Mousavi S, Hu MI, Varghese JM, Zafereo ME, Debnam JM. Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. J Clin Ultrasound. e-Pub 2020. PMID: 32045024.
- Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Ann Surg Oncol 25(11):3380-3388, 2018. e-Pub 2018. PMID: 30022274.
- Gayed IW, Karni RJ, Wan DQ, Varghese JM, Wirfel KL, Won KS, Joseph UA. Interpretation of Tc-99m Sestamibi Parathyroid. Dove Press 2017(10):1-7, 2016. e-Pub 2016.
- Olejarski J, Yang M, Varghese J. Follicular thyroid carcinoma presenting as a soft tissue thigh mass. Lancet Diabetes Endocrinol 2(4):348, 2014. e-Pub 2014. PMID: 24703053.
- Machicado JD, Varghese JM, Orlander PR. Cabergoline-induced pneumocephalus in a medically treated macroprolactinoma. J Clin Endocrinol Metab 97(10):3412-3, 2012. e-Pub 2012. PMID: 22802088.
- Varghese J, Ayala-Ramirez M, Rich T, Rohren E, Rao P, Jimenez C. Novel germline SDHD mutation: diagnosis and implications to the patient. Fam Cancer 10(2):365-71, 2011. e-Pub 2011. PMID: 21318381.
Invited Articles
- Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. Bone 158, 2022. e-Pub 2021. PMID: 33631354.
- Mazzaglia PJ, Varghese J, Habra MA. Evaluation and Management of Adrenal Neoplasms: Endocrinologist and Endocrine Surgeon Perspectives. Abdominal Radiology (NY)(45):1001–1010. e-Pub 2020. PMID: 32189021.
- Varghese J. Hypothyroidism. Medscape, 2019. e-Pub 2019.
- Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes 24(3):208-214, 2017. e-Pub 2017. PMID: 28277340.
- Varghese J, Rich T, Jimenez C. Benign familial hypocalciuric hypercalcemia. Endocr Pract 17 Suppl 1:13-7, 2011. e-Pub 2011. PMID: 21478088.
- Varghese J, Gómez K, Jiménez C. Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res 2011:815826, 2011. e-Pub 2011. PMID: 21687607.
Review Articles
- Varghese JM, Grubbs, E, Baxter, S, Lango, M, Galvan, A, Cunningham, C, Vandijk, S, Langer, M, Moronta, S, Collins, R, Digenna, C. "A Thyroid Cancer-Specific Utility Index: Development and Valuation of the TCQOLI (Thyroid Cancer Quality Of Life)". Thyroid, 2026. e-Pub 2026.
- Jimenez, C, Armaiz-Pena, G, Dahia, PL, Lu, Y, Toledo, RA, Varghese, J, Habra, MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma. Cancers 14(3), 2022. e-Pub 2022. PMID: 35158739.
- Jimenez, C, Xu, G, Varghese, J, Graham, PH, Campbell, M, Lu, Y. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas. Current oncology reports 24(1):89-98, 2022. e-Pub 2022. PMID: 35061191.
- Varghese J, Rohren E, Guofan X. Radioiodine Imaging and Treatment in Thyroid Disorders. Neuroimaging Clin N Am 31(3):337-344, 2021. e-Pub 2021. PMID: 34243868.
Professional Educational Materials
- Lu HL, Varghese JM, Beavers T, Brewster A, Fleckenstein ON, Guise TA, Gilmore K, Hortobagyi GN, Kazantsev T, Rollins JL, Strom EA. Survivorship - Breast Cancer: Bone Health. MD Anderson Cancer Center, 2024.
- Varghese JM, Bevers T, Garcia W, Gilmore K, Kazansev T, Lu H, Nelson A, Rollins JL. Survivorship - Gynecologic Cancer: Bone Health. MD Anderson Cancer Center, 2024.
- Anscher M, Augustyn A, Ayoub Z, Varghese J, et al. The MD Anderson Cancer Center Handbook of Radiation Oncology. Wolters Kluwer, 2019.
- Varghese JM. Glycemic Task Force Educational Videos.
Other Articles
- Varghese JM, Chen L, Brondani V, Marcal L, Jimenez C, Shah A, Habra M, Campbell M Gemcitabine Oxaliplatin Combination in Patients with Advanced Adrenocortical Carcinoma Open Access 9(Supplement_1), 2025.
- Daher, M, Varghese, J, Gruschkus, SK, Jimenez, C, Waguespack, SG, Bedrose, S, Altameemi, L, Bazerbashi, H, Naing, A, Subbiah, V, Campbell, M, Shah, AY, Zhang, M, Sheth, RA, Karam, JA, Wood, CG, Perrier, ND, Graham, PH, Lee, JE, Habra, MA Erratum to. Journal of Clinical Endocrinology and Metabolism 107(8):E3544, 2022. PMID: 35536657.
- Varghese JM, Balderrama-Brondani V, Marcal L, Moussa M, Long J, Waguespack S, Jimenez C, Graham P, Fisher S, Perrier N, Shah A, Sheth R, Zhang M, Campbell M, Habra M Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A retrospective cohort study.
Abstracts
- Varghese JM, Graham PH, Brondani VB, Habra MA, Waguespack SG, Jimenez C, Fisher SB, Perrier ND, Campbell M. Circulating Tumor DNA evaluation in the surgical management of Adrenocortical Carcinoma: A retrospective cohort study. 11th Biennial Congress of The European Society of Endocrine Surgeons, 2026.
- Jimenez C, Habra MA, Campbell M, Tamsen G, Cruz-Goldberg D, Long J, Bassett R, Dantzer R, Balderrama V, Varghese J, Waguespack S, Lu Y. A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial. Endocrine Abstracts 98(C5):NANETS 2023, 2023. e-Pub 2023.
- Brondani VB, Griffin AM, Owen TJ, Merriman KW, Varghese JM, Jimenez C, Waguespack, SG, Graham PH, Campbell MT, Hassan MM, Habra MA. Changes in the Incidence and Geographical Distribution of Adrenocortical Carcinoma: A Retrospective Analysis of a State Cancer Registry. ENDO 2023, Chicago, Illinois, 2023. e-Pub 2023.
- Campbell MT, Jimenez C, Long JP, Varghese J, Shah A, Zhang M, Tamsen G, Habra MA. 1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma. Annals of Oncology, 2022. e-Pub 2022.
- Al-Ward R, Varghese J, Jimenez C. High Specific Activity Iodine-131 Metaiodobenzylguanidine for the Treatment of Advanced Pheochromocytoma: A Real-World Study, 2022. e-Pub 2022.
- Tetlay M, Vodopivec D, Zafereo M, Varghese J, Cabanillas M. Benralizumab stimulating growth of thyroid cancer by activating Graves’ Disease – A Case Report, 2022. e-Pub 2022.
- Fazeli S, Zafereo M, Wang J, Varghese J. Post Thyroidectomy Hypocalcemia Prevention and Optimized Management. AHNS 10th International Conference on Head and Neck Cancer, 2021. e-Pub 2021.
- Raty S, Thosani S, Gaeta S, Chen K, Taylor J, Thomas L, Weschler A, Horner A, Bowe C, Cavalier J, Benitez S, Gumban D, Folloder J, Drew T, Mart D, Shin D, Giang K, Monroe S, Koom-Dadzie K, Rajkot N, Richardson G, Tran J, Mathew J, Best C, Brady V, Lavis V, Wilson M, Levesque C, Ortiz M, Varghese J, Varghese S, Crowder V, John B, Ong J, Verallo C, Fajardo J, Ta-Ekasingh M, Parlikh M, Grami P, Kaur H, Estrella J, Bruno J, Horng M, Moser T, Walton N, Nugent A, Johnson C, Popat, U, Rizk M, Novicke B, DeCarlo R, Ali E, McCollough R, Warren M, Lopez K, Marts D, Goldschmidt P, Rice J, Zaghian M, Stone D, Kaufman L, Jawe N. Glycemic Action team (GlyCAT): reducing inpatient DKa in cancer patients. IHI patient safety congress, 2021. e-Pub 2021.
- Jeun R, Best C, Iyer P, Lavis V, Varghese J, Glitza Oliva I, Dadu R, Thosani SN. “Immune Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: Observations at a Cancer Center.”, 2021. e-Pub 2021.
- Bedrose S, Altameemi L, Daher, M, Jimenez C, Varghese J, Tamsen De Rosa G, Campbell M, Habra MA. Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma. ENDO 2020, 2020. e-Pub 2020.
- Varghese J, Salgado S, Hu M, Thosani S, et al. Post-Thyroidectomy Hypoparathyroidism Management: A Prospective Quality Improvement Initiative at a Single Tertiary Center. AACE 28th Annual Scientific & Clinical Congress, 2019. e-Pub 2019.
- Varghese J, Iyer P, Best C, Lavis V, et al. Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: A Cancer Center Experience. Endo 2018, Chicago, Illinois, 2018. e-Pub 2018.
- Varghese J, Chiu C, Orlander P, Wirfel K, et al. Bone Turnover in Postmenopausal Women with Hyponatremia. American Society for Bone and Mineral Research Annual Meeting 2017, 2017. e-Pub 2017.
- Varghese J. Anaplastic Infiltrating Glioma Presenting As Isolated Hyperprolactinemia. American Association of Clinical Endocrinologists (AACE) Annual Meeting, Nashville, Tennessee, 2015. e-Pub 2015.
- Varghese J. Ectopic PTH: A Rare Case of Hypercalcemia in Malignancy. American Association of Clinical Endocrinologists (AACE) Annual Meeting, Nashville, Tennessee, 2015. e-Pub 2015.
- Varghese J. The Man Who Stopped Speaking: An Unusual Presentation of an Osmotic Demyelination Syndrome in a Patient with Panhypopituitarism. American Academy of Neurology 67th Annual Meeting, Washington, DC, April 2015, 2015. e-Pub 2015.
- Varghese J. Syndrome in a Patient with Panhypopituitarism. American Academy of Neurology 67th Annual Meeting, Washington, DC, 2015. e-Pub 2015.
- Varghese J. Adrenal Insufficiency Leading to Diagnosis of Metastatic Cancer. The Endocrine Society 97th Annual Meeting, San Diego, California, 2015. e-Pub 2015.
- Varghese J. The Man Who Stopped Speaking: An Unusual Presentation of Osmotic Demyelination in a Patient with Pan-hypopituitarism. American Association of Clinical Endocrinologists (AACE) Annual Meeting, Houston, Texas, 2014. e-Pub 2014.
- Varghese J. Bilateral Adrenal Hemorrhage: A Rare Complication of Heparin Induced Thrombocytopenia. The Endocrine Society 96rd Annual Meeting, Chicago, Illinoios, 2014. e-Pub 2014.
- Varghese J. Dopamine Agonist-Resistant Prolactinoma: A Potential Role of Raloxifene. The Endocrine Society 93rd Annual Meeting, Chicago, Illinois, June 2014, 2014. e-Pub 2014.
- Varghese J. Post Thyroidectomy Hungry Bone Syndrome - A Rare Complication in Graves Disease. The Endocrine Society 95th Annual Meeting, San Francisco, California, 2013. e-Pub 2013.
- Varghese J. Mediastinal Paraganglioma: the MD Anderson Experience. The Endocrine Society 93rd Annual Meeting, Boston, Massachusetts, 2011. e-Pub 2011.
- Varghese J. Role of Cytotoxic Chemotherapy in Advanced Differentiated Thyroid Cancer–Review of the MD Anderson Experience. 14th International Thyroid Congress, Paris, France, 2010. e-Pub 2010.
- Varghese JM, Cunningham C, van Dijk S, Langer M, Moronta S, Herman T, Collins R, Digennaro C, Galvan A, Lango M, Jalali M, Fisher S, Grubbs E, Donelan K, Swan J. A Thyroid Cancer-Specific Utility Index: Development and Valuation of the TCQOLI (Thyroid Cancer Quality Of Life).
- Varghese JM. Positive Fluorodeoxyglucose (FDG) Uptake: An early Indicator of Immune Checkpoint Inhibitor Related Hypophysitis. American College of Physicians (ACP) Internal Medicine Meeting.
- Varghese JM, Al Zaki A, Sutton M, Rehman A, Coa Le C, Gammon S, Napoli A, Yang P, Saini N, Ahmed S, Issa G, Kebriaei P, Davies M, Shpall E, Flynt L, Neelapu S, Piwnica-Worms D. Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy. ASH Annual Meeting.
- Varghese JM, Chahla B, Bassett R, Hassan M, Habra MA. Association of Epidemiological and Risk Factors with Adrenocortical Carcinoma in Adults in the United States. ENDO 2025.
- Varghese JM, Chen L, Brondani VB, Marcal LP, Jimenez C, Shah AY, Habra MA, Campbell MT. Gemcitabine Oxaliplatin Combination in Patients with Advanced Adrenocortical Carcinoma.
- Varghese JM, Brondani VB, Moussa MJ, Shah AY, Graham PH, Jimenez C, Campbell MT, Habra MA. Circulating Tumor DNA Analysis in Adrenocortical Carcinoma - A First Retrospective Cohort Study. ENDO 2025.
- Varghese JM, Zhang L, Tisserand G, Shen Y, Salehi M, Amar L, Cui Y, Świątkowska-Stodulska R, Moog S, Liu J, Gubbi S, Falhammar H, Kocjan T, Igaz P, Hadoux J, Young W, Remde H, Babińska A, de Miguel V, Beuschlein F, Liu L, Palmieri S, Jiang J, Fischer A, Carreira A, Parasiliti-Caprino M, Nölting S, Zhou Y, Prodanov T, Bancos I, Fassnacht M, Jimenez C, Alkaissi H, Tong A, Pacak K, Crona J. Safety of biopsy in phaeochromocytoma and paraganglioma: an international multi-centre cohort study. ENS@T2025.
- Varghese JM, Chacko SR, Villavicencio C, Yu K, Waguespack SG, Lin L, Belaya Z, Bandgar T, Ragnarrson O, Altieri B, Newman A, Vibhatavata P, Tóth M, Varlamov E, Badiu C, Paissan A, St-Jean M, Falhammar H, Imamudeen N, Haberbosch L, Bobrowicz M, Tabarin A, Shah R, Gadelha MR, Peerson A, Young, Jr. WF, Kaplan J, Habra MA, Golounina O, Melnichenko G, Lila AR, Yamichannaiah C, Bancos I. Management and Outcomes of Ectopic ACTH Syndrome: an International Multicenter Retrospective Study. ENDO 2025.
Book Chapters
- Varghese JM, Khan H, Shah R, Khan S, Thosani SN. Manual of Medical Oncology. In: Endocrine and Metabolic Complications of Cancer Therapy, 2025.
- Varghese JM, Ngo S. Challenging Cases in Immunotherapy Related Organ Toxicities. In: Hypophysitis Post Immune Checkpoint Inhibitor Therapy. Springer Cham, 51-56, 2023.
- Varghese, J, Ali, MS. Thyroid cancer. In: Cardio-Oncology Practice Manual. Elsevier, 383-387, 2022.
- Varghese, J, Best, CJ. Endocrine. In: Managing Immunotherapy Related Organ Toxicities. Springer, 59-79, 2022.
- Jeun R, Thosani S, Varghese J. In: The MD Anderson Manual of Medical Oncology, 4e. McGraw Hill, 2022.
- Varghese JM, Rohren E, Guofan C. Radioiodine Imaging and Treatment in Thyroid Disorders. In: Neuroimaging Clinics, Thyroid and Parathyroid Imaging. Elsevier, 337-344, 2021.
- Varghese JM. Oncology Hospital Medicine: A Guide for the Frontline Clinicians. In: Adrenal Insufficiency. Springer Nature, 12.
- Ngo S, Varghese JM. Hypophysitis post immune checkpoint inhibitor therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer.
Patient Reviews
CV information above last modified March 06, 2026